SHTDY fundamentals
An in-depth look to Sinopharm Group Co. Ltd. operating, investing, and financing activities
SHTDY free cash flow for H2 23 is 8.15 B USD. For 2023, SHTDY free cash flow was 1.64 B USD and operating cash flow was 1.93 B USD.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
TTM